Abstract
There are both pharmacologic and practical reasons for recommending intraoperative intraperitoneal chemotherapy. From a pharmacologic point of view, direct installation of selected drugs into the peritoneal cavity results in a large increase in the amount of chemotherapy that reaches abdominal and pelvic surfaces. This pharmacologic advantage is the result of the peritoneal-plasma barrier. Molecules of large hydrophyllic drugs leave the peritoneal cavity more slowly than they are metabolized systemically. Three-fore, a great concentration difference exists at all times between drug concentration within the peritoneal cavity and drug concentration in the plasma [1,2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Jacquet P. The peritoneal-plasma barrier. In: Sugarbaker PH. ed. Peritoneal carcinomatosis: Principles of Management. Norwell, MA: Kluwer Academic Publishers, 1996, pp 53–63.
Myers CE, Collins JM. Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1983;1:395–407.
Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW, Meyers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 1981;41:1916–1922.
Rosenhein H, Blake D, McIntryre P, Parmly T. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 1978;6:106–110.
Markman M, Cleary S, Howell SB, Lucas WE. Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg Gynecol Obstet 1986;162:445–448.
Fujimura T, Yonemura Y, Fushida S, Urade M, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 1990;65:65–71.
Gilly FN, Carry PY, Brachet A, et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol Tumor Pharmacother 1992;9:177–181.
Los G, Sminia P, Wondergem J, Mutsaers PHA, et al. Optimization of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991;27:472–477.
Fujimoto S, Takahashi M, Endoh F, Shresta RD, et al. A clinical study combining surgery with intraoperative pelvic hyperthermochemotherapy to prevent local recurrence of rectal cancer. Ann Surg 1991;213:43–47.
Yonemura Y, Ninomiya I, Kaji M, Sugiyama K, et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 1995;19:450–455.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Sugarbaker, P.H., Averbach, A.M., Jacquet, P., Stephens, A.D., Stuart, O.A. (1996). A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. In: Sugarbaker, P.H. (eds) Peritoneal Carcinomatosis: Principles of Management. Cancer Treatment and Research, vol 82. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1247-5_26
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1247-5_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8531-1
Online ISBN: 978-1-4613-1247-5
eBook Packages: Springer Book Archive